1 / 8

MALACHITE study : OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1

MALACHITE study : OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1. Randomisation Open-label. W12. W24. W48. Design. 18-65 years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I) Failure to prior PEG-IFN + RBV (MALACHITE-II) No cirrhosis

vickye
Télécharger la présentation

MALACHITE study : OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 Randomisation Open-label W12 W24 W48 • Design 18-65 years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I) Failure to prior PEG-IFN + RBV (MALACHITE-II) No cirrhosis No HBV or HIV co-infection GT1a naïve N = 69 * N = 34 GT1b naïve N = 84 * N = 83 * Randomisation wasstratified on IL28B (CC or non-CC) N = 41 Experienced N = 101 ** ** Randomisation was stratified on genotype (1a or 1b) and previous response to PEG-IFN + RBV (null response, partial response, relapse) N = 47 Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  2. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 • Treatment regimens • Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r): 25/150/100 mg qd = 2 tablets • Dasabuvir (DSB) : 250 mg bid • TVR: 750 mg tid, 8h apart • PEG-IFNa-2a : 180 mg SC once weekly • RBV: 1000 or 1200 mg/day (bid dosing) according to body weight (< or ≥ 75 kg) • In TVR groups, additional 12 or 36 weeks of PEG-IFN+ RBV depended on virologic response at treatment W4-12 • Primary efficacy endpoint • MALACHITE-I: Non inferiority of OBV/PTV/r + DSB + RBV compared to TVR + PEG-IFN + RBV in genotype 1a and of OBV/PTV/r + DSB compared to TVR + PEG-IFN + RBV in genotype 1b: SVR12 (HCV RNA < 25 IU/ml) by intention to treat (lower margin of the 2-sided 95% CI for the difference with TVR = - 10.5%) • MALACHITE-II: % of patients achieving SVR12 between treatment arms using a logistic regression model with treatment arm, baseline log10 HCV RNA level, HCV subgenotype (1a, non-1a), and previous PEG-IFN + RBV treatment response (relapse, partial response, null response) Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  3. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 Baseline characteristics and patient disposition (MALACHITE-I, treatment-naïve) * Among the 75 patients in the TVR groups, 59 received 24 weeks of PEG-IFN + RBV, 16 received 48 weeks Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  4. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 Baseline characteristics and patient disposition (MALACHITE-II, Treatment-experienced) Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  5. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 SVR12 (HCV RNA < 25 IU/ml), % (95% CI) MALACHITE-I (treatment-naïve) MALACHITE-II(treatment-experienced) % 99 (97-100) 99 (97-100) 98 (94-100) 97 (93-100) OBV/PTV/r + DSV + RBV 100 82 (68-96) OBV/PTV/r + DSV 78 (66-91) TVR + PEG-IFN + RBV 80 66 (53-79) 60 Genotype 1a: non-inferiority of OBV/PTV/r + DSV + RBVto TVR + PEG-IFN + RBV Genotype 1b: non-inferiority and superiority of OBV/PTV/r + DSV and of OBV/PTV/r + DSV + RBV to TVR + PEG-IFN + RBV 40 20 N 69 34 84 83 41 101 47 0 Genotype 1a Genotype 1b All patients * These 3 patients were adherent. At the time of failure, detection of resistance variants at in NS3, NS5A, and/or NS5B that were not present at baseline ** Reinfection (Genotype 2a) *** Missing data or premature discontinuation Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  6. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 Adverse events * Hot flush and fatigue Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  7. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 Laboratory abnormalities, % Patient-reported outcomes • SF-36v2 self-administered questionnaire: overall, the difference between the 2 regimens in the changes from baseline in Mental Component Summary and Physical Component Summary throughout the treatment and post-treatment periods in both treatment-naïve and treatment-experienced patients favored the OBV/PTV/r + DSV + RBV regimen Dore G. J Hepatol 2016; 64:19-28 MALACHITE

  8. MALACHITE study: OBV/PTV/r + DSV + RBV versus telaprevir + PEG-IFN + RBV in genotype 1 • Summary • This is the first head-to-head study of an all-oral, DAA (OBV/PTV/r + DSV + RBV) and a PEG-IFN-containing (TVR + PEG-IFN + RBV) regimen that quantitatively compares efficacy and safety benefits in treatment-naïve and treatment-experienced HCV genotype 1-infected patients • SVR12 rate was numerically higher with OBV/PTV/r + DSV + RBV (97-99%) than with TVR + PEG-IFN + RBV (66-82%) regardless of subgenotypeor prior treatment status • Better tolerability of OBV/PTV/r + DSV +RBV • Higher improvement in mental and physical health in patients receiving OBV/PTV/r + DSV + RBV • Limitations • Exclusion of cirrhosis • Absence of black patients • Low number of experienced patients with genotype 1a Dore G. J Hepatol 2016; 64:19-28 MALACHITE

More Related